Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adagloxad simolenin - OBI Pharma

Drug Profile

Adagloxad simolenin - OBI Pharma

Alternative Names: Adagloxad simolenin; Cancer vaccine Globo-H; Globo H-KLH; Globo-H vaccine; OBI 822; OBI-822/OBI-821; OPT-22; OPT-822/821; OPT-822/OPT-821

Latest Information Update: 26 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer OBI Pharma
  • Class Cancer vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 01 Aug 2019 OBI Pharma completes a phase II trial in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, China, Hong Kong, India, South Korea and Taiwan (NCT01516307)
  • 05 Dec 2018 Phase-III clinical trials in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT03562637)
  • 10 Aug 2018 Chang Gung Memorial Hospital plans a phase II trial for Hepatocellular carcinoma (First-line therapy, Combination therapy, Adjuvant therapy) in Taiwan (NCT03608878)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top